Skip to main content
. 2019 Nov 20;20(23):5826. doi: 10.3390/ijms20235826

Figure 7.

Figure 7

Olcegepant decreases leukemic burden and stem cell properties in a mouse model of AML. (a,b) Healthy C57BL/6 mice (4–5 per group) were treated with 0, 5, or 10 mg/kg olcegepant by daily i.p. injection from day 1–14 after a sublethal irradiation. ns, not significant, ** p < 0.01, *** p < 0.001, Student’s two-tailed t-test. (a) Total body weight at the end of treatment. (b) Relative abundance of LSK cells, CMPs, and GMPs among BM MNCs. (c–f) C57BL/6 mice were transplanted with LCLSK_MA9 and treated with 0 or 10 mg/kg olcegepant by daily i.p. injection from day 7–18 after transplantation. * p < 0.05, ** p < 0.01, Student’s two-tailed t-test. (c) Leukemic burden: proportion of Venus+ (leukemic) cells in bone marrow (BM) and spleen. n = 6/group. (d) Leukemic cell (LC) differentiation: proportion of Gr1+ cells among Venus+ CD11b+ BM cells. (e) Abundance of the LSC enriched Lin− Sca1− c-Kit+ CD34+ CD16/CD32hi (LSCe) population among leukemic (Venus+) cells (LCs) in BM. (f) Cell cycle distribution of LSCe. Significance indicator refers to G0 only. (d–f) n = 5/group.